To the Editor: In their meta-analyses1,2 Dr Eikelboom and colleagues compare thrombolytic therapies for acute myocardial infarction (MI). Since meta-analyses of bolus-vs-infusion trials reveal no differences in efficacy, the choice of agent should be based on safety and cost. With regard to safety, the only statistically significant difference in the meta-analyses was a reduction in intracranial hemorrhages with infusion agents.1,2